Evidence map›Paper›PMID 39338350›Full record

ReviewPharmaceuticals (Basel, Switzerland)2024

Review: Neuroprotective Nanocarriers in Glaucoma.

Kun Pei, Maria Georgi, Daniel Hill, Chun Fung Jeffrey Lam, Wei Wei, Maria Francesca Cordeiro

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kun PeiUCL Institute of Ophthalmology, London EC1V 9EL, UK.
Maria GeorgiSt Mary's Hospital, Imperial College Healthcare NHS Trust, London W2 1NY, UK.ORCID 0000-0001-6509-4691
Daniel HillUCL Institute of Ophthalmology, London EC1V 9EL, UK.
Chun Fung Jeffrey LamGKT Medical School, Guy's Campus, Great Maze Pond, London SE1 1UL, UK.
Wei WeiDepartment of Surgery & Cancer, Imperial College London, London SW7 5NG, UK.
Maria Francesca CordeiroUCL Institute of Ophthalmology, London EC1V 9EL, UK.ORCID 0000-0001-8663-6525

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glaucoma stands as a primary cause of irreversible blindness globally, characterized by the progressive dysfunction and loss of retinal ganglion cells (RGCs). While current treatments primarily focus on controlling intraocular pressure (IOP), many patients continue to experience vision loss. Therefore, the research focus has shifted to therapeutic targets aimed at preventing or delaying RGC death and optic nerve degeneration to slow or halt disease progression. Traditional ocular drug administration, such as eye drops or oral medications, face significant challenges due to the eye's unique structural and physiological barriers, which limit effective drug delivery. Invasive methods like intravitreal injections can cause side effects such as bleeding, inflammation, and infection, making non-invasive delivery methods with high bioavailability very desirable. Nanotechnology presents a promising approach to addressing these limitations in glaucoma treatment. This review summarizes current approaches involving neuroprotective drugs combined with nanocarriers, and their impact for future use.

Indexed as

glaucomananocarriersnanomedicineneuroprotectionneuroprotectiveocular neurodegenerative diseaseretinal ganglion cell

Identifiers

PMID39338350
PMCPMC11435059

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.